Amgen's Avastin biosimilar meets in Phase III

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said ABP 215, a biosimilar to Avastin bevacizumab, met the primary and secondary endpoints in a Phase III study to treat non-small cell lung cancer (NSCLC).

Amgen said ABP 215 showed clinical equivalence to its Avastin reference product in the 642-patient study. The biosimilar produced objective response rates within a pre-specified margin in adults with advanced non-squamous NSCLC, meeting the study's primary endpoint. ...